Cargando…

Eribulin mesylate as a microtubule inhibitor for treatment of patients with metastatic breast cancer

Metastatic breast cancer (MBC) remains an incurable disease, with the goals of care aimed at maximizing the patient’s duration and quality of life. Treatment options for MBC have become more efficacious and numerous. In addition to endocrine and chemotherapy agents, a number of targeted agents, incl...

Descripción completa

Detalles Bibliográficos
Autores principales:	Muñoz-Couselo, Eva, Pérez-García, José, Cortés, Javier
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2011
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3233277/ https://www.ncbi.nlm.nih.gov/pubmed/22162924 http://dx.doi.org/10.2147/OTT.S16392

Ejemplares similares

Eribulin mesylate in the treatment of metastatic breast cancer
por: Jain, Sarika, et al.
Publicado: (2012)

Clinical Utility of Eribulin Mesylate in the Treatment of Breast Cancer: A Chinese Perspective
por: Yuan, Peng, et al.
Publicado: (2021)

Cost Effectiveness Analysis of Eribulin Mesylate as a Treatment for Metastatic Breast Cancer in Spain: Management in the Later Line of Therapy
por: Tremblay, Gabriel, et al.
Publicado: (2015)

Investigating the Role of CTCs with Stem/EMT-like Features in Metastatic Breast Cancer Patients Treated with Eribulin Mesylate
por: Papadaki, Maria A., et al.
Publicado: (2022)

Health-related quality of life in patients with locally advanced or metastatic breast cancer treated with eribulin mesylate or capecitabine in an open-label randomized phase 3 trial
por: Cortes, Javier, et al.
Publicado: (2015)

Phase III Open-Label Randomized Study of Eribulin Mesylate Versus Capecitabine in Patients With Locally Advanced or Metastatic Breast Cancer Previously Treated With an Anthracycline and a Taxane
por: Kaufman, Peter A., et al.
Publicado: (2015)

Prospective Analysis of Patients with Metastatic Breast Cancer receiving Eribulin Mesylate as Second or More Lines of Chemotherapy: An Indian Experience
por: Srinivasa, BJ, et al.
Publicado: (2018)

Eribulin Mesylate in Pretreated Breast Cancer Patients: A Multicenter Retrospective Observational Study
por: Gamucci, Teresa, et al.
Publicado: (2014)

Eribulin Mesylate-related Multifocal Demyelinating Neuropathy with Myokymia in a Breast Cancer Patient
por: Tsunogae, Marie, et al.
Publicado: (2021)

Subgroup Analyses from a Phase 3, Open-Label, Randomized Study of Eribulin Mesylate Versus Capecitabine in Pretreated Patients with Advanced or Metastatic Breast Cancer
por: Twelves, Chris, et al.
Publicado: (2016)

Eribulin Mesylate Combined with Local Treatment for Brain Metastasis from Breast Cancer: Two Case Reports
por: Byun, Kyung-Do, et al.
Publicado: (2016)

Eribulin mesylate versus ixabepilone in patients with metastatic breast cancer: a randomized Phase II study comparing the incidence of peripheral neuropathy
por: Vahdat, Linda T., et al.
Publicado: (2013)

Eribulin mesylate in patients with refractory cancers: a Phase I study
por: Mukohara, Toru, et al.
Publicado: (2011)

Pharmacokinetics of eribulin mesylate in cancer patients with normal and impaired renal function
por: Tan, Antoinette R., et al.
Publicado: (2015)

Eribulin mesylate use as third-line therapy in patients with metastatic breast cancer (VESPRY): a prospective, multicentre, observational study
por: Adamo, Vincenzo, et al.
Publicado: (2019)

Efficacy and safety of eribulin mesylate in advanced soft tissue sarcomas
por: Noujaim, Jonathan, et al.
Publicado: (2016)

Eribulin mesylate exerts antitumor effects via CD103
por: Oya, Kazumasa, et al.
Publicado: (2023)

Health-related quality of life in patients receiving first-line eribulin mesylate with or without trastuzumab for locally recurrent or metastatic breast cancer
por: Schwartzberg, Lee, et al.
Publicado: (2019)

Eribulin Mesylate Targets Human Telomerase Reverse Transcriptase in Ovarian Cancer Cells
por: Yamaguchi, Satoko, et al.
Publicado: (2014)

Clinical benefit of treatment with eribulin mesylate for metastatic triple‐negative breast cancer: Long‐term outcomes of patients treated in the US community oncology setting
por: Mougalian, Sarah S., et al.
Publicado: (2018)

A Case of Brain Metastases from Breast Cancer Treated with Whole-Brain Radiotherapy and Eribulin Mesylate
por: Nieder, Carsten, et al.
Publicado: (2012)

Eribulin mesylate reduces tumor microenvironment abnormality by vascular remodeling in preclinical human breast cancer models
por: Funahashi, Yasuhiro, et al.
Publicado: (2014)

Phase II trial of eribulin mesylate as a first- or second-line treatment for locally advanced or metastatic breast cancer: a multicenter, single-arm trial
por: Hayashida, Tetsu, et al.
Publicado: (2018)

Neoadjuvant eribulin mesylate following anthracycline and taxane in triple negative breast cancer: Results from the HOPE study
por: Di Cosimo, Serena, et al.
Publicado: (2019)

Tumour biology, metastatic sites and taxanes sensitivity as determinants of eribulin mesylate efficacy in breast cancer: results from the ERIBEX retrospective, international, multicenter study
por: Dell’Ova, Mélodie, et al.
Publicado: (2015)

Case Studies in the Management of Metastatic Breast Cancer with Eribulin
por: Wilks, Sharon, et al.
Publicado: (2015)

Eribulin for the treatment of metastatic breast cancer: an update on its safety and efficacy
por: Doherty, Mark K, et al.
Publicado: (2015)

Phase 2 study of eribulin mesylate as first-line therapy for locally recurrent or metastatic human epidermal growth factor receptor 2-negative breast cancer
por: McIntyre, Kristi, et al.
Publicado: (2014)

Eribulin mesylate induces bone mass loss by promoting osteoclastic bone resorption in mice
por: Ishizaka, Takahiro, et al.
Publicado: (2023)

Erratum to: Phase 2 study of eribulin mesylate as first-line therapy for locally recurrent or metastatic human epidermal growth factor receptor 2-negative breast cancer
por: McIntyre, Kristi, et al.
Publicado: (2014)

Efficacy of eribulin in women with metastatic breast cancer: a pooled analysis of two phase 3 studies
por: Twelves, Chris, et al.
Publicado: (2014)

High absolute lymphocyte counts are associated with longer overall survival in patients with metastatic breast cancer treated with eribulin—but not with treatment of physician’s choice—in the EMBRACE study
por: Miyoshi, Yasuo, et al.
Publicado: (2020)

Eribulin for the treatment of metastatic breast cancer: an update on its safety and efficacy [Corrigendum]
Publicado: (2015)

Eribulin Mesylate Improves Cisplatin-Induced Cytotoxicity of Triple-Negative Breast Cancer by Extracellular Signal-Regulated Kinase 1/2 Activation
por: Ko, Hyemi, et al.
Publicado: (2022)

Bone metastases: Causes, consequences and therapeutic opportunities
por: Perez-Garcia, Jose, et al.
Publicado: (2013)

Erratum to: Efficacy of eribulin in women with metastatic breast cancer: a pooled analysis of two phase 3 studies
por: Twelves, Chris, et al.
Publicado: (2015)

Impact of the number of prior chemotherapy regimens on outcomes for patients with metastatic breast cancer treated with eribulin: A post hoc pooled analysis
por: Cortes, Javier, et al.
Publicado: (2019)

A randomized trial of eribulin monotherapy versus eribulin plus anlotinib in patients with locally recurrent or metastatic breast cancer
por: Liu, B., et al.
Publicado: (2023)

Efficacy of eribulin for metastatic breast cancer based on localization of specific secondary metastases: a post hoc analysis
por: O’Shaughnessy, Joyce, et al.
Publicado: (2020)

Safety Results and Analysis of Eribulin Efficacy according to Previous Microtubules-Inhibitors Sensitivity in the French Prospective Expanded Access Program for Heavily Pre-treated Metastatic Breast Cancer
por: Sabatier, Renaud, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_2v8eqvj6ifkk2lumha8mmlllbk